ClaimsFiler, a FREE shareholder information service, reminds investors
that they have only until June 19, 2018 to file lead plaintiff
applications in a securities class action lawsuit against Myriad
Genetics, Inc. (NasdaqGS: MYGN). Investor losses must relate to
purchases of the Company’s securities between August 13, 2014 and March
12, 2018. This action is pending in the United States District Court for
the District of Utah.
Myriad investors should visit us at https://www.claimsfiler.com/cases/view-myriad-genetics-securities-litigation
or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
On March 12, 2018, Myriad revealed that it received a subpoena from the
Department of Health and Human Services, regarding “an investigation
into possible false or otherwise improper claims submitted for payment
under Medicare and Medicaid,” relating to the Company’s cancer testing
dating back to January 1, 2014 to the date of the subpoena’s issuance.
On this news, the price of Myriad’s shares plummeted over 12.14%
ClaimsFiler has a single mission: to serve as the information source to
help retail investors recover their share of billions of dollars from
securities class action settlements. ClaimsFiler’s team of experts
monitor the securities class action landscape and cull information from
a variety of sources to ensure comprehensive coverage across a broad
range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005769/en/